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ABSTRACT: 
 The objective of this project is to report oncologic and functional outcomes 
for a cohort of patients with supraglottic squamous cell carcinoma (SSCC) treated 
in a multidisciplinary setting including the use of transoral laser microsurgery 
(TLM). A retrospective observational study at Yale New Haven Hospital, 
academic teaching hospital was performed.  A total of 56 patients without 
evidence of distant metastasis at presentation treated for SSCC  between 
January 1, 2003 and December 31, 2007 were identified.  The main outcome 
measures include overall survival (OS), locoregional and distant recurrence, and 
the incidence of tracheostomy and gastrostomy tube requirement.   
 Of the 56 patients, 22 (39%) were treated with TLM, 23 (41%) with 
definitive radiation (XRT) based therapy, and 11 (20%) with total laryngectomy 
(TL).  Chronic tracheostomy requirement for the TLM, XRT, and TL groups was 
0% (0/21), 35% (7/20) and 100% (11/11).  Long term gastrostomy tube (PEG) 
use for the TLM, XRT, and TL groups was 15% (3/20), 36% (4/11) and 50% 
(5/10) respectively.  Two year OS for TLM, TL, and XRT were 86% (18/21), 80% 
(8/10), and 52% (12/23) respectively.  Controlling for age, stage, and treatment 
on multivariate analysis, younger age and treatment with either TL or TLM were 
significantly associated with improved survival. 
 In conclusion, transoral laser microsurgery, especially when employed in a 
multimodal approach including adjuvant chemoradiotherapy, offers acceptable 
oncologic results and good functional outcomes.  
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INTRODUCTION 
 
Supraglottic squamous cell carcinoma is a challenging disease affecting the parts 
of the human body involved in how a person interacts in the world.  There has 
been considerable advancement in the available treatment options for 
supraglottic SCCA over the past decades.  Currently, the goal of treatment is to 
optimize the chance of cure while minimizing the impact of therapy on a person’s 
quality of life.  This paper will discuss and investigate the current state of 
treatment for supraglottic cancer. 
 
 
EPIDEMIOLOGY: 
 
Cancer of the head and neck most commonly affects regions of the aerodigestive 
tract.  Head and neck cancer comprises primary malignancies located in 
anatomically related regions including the oral cavity, oropharynx, nasopharynx, 
larynx, and hypopharynx.  When taken in conglomerate, head and neck cancer 
has the sixth greatest incidence worldwide, with approximately 600,000 new 
cases annually. 1  More than 40,000 new cases of head and neck cancer in the 
United States are diagnosed annually.  Men are two to three times more likely to 
be diagnosed with HNSCC than women and the median age of diagnosis is 60 
years old.  However, recent observations suggest that the number of new cases 
in young adults may be increasing. 2  Tumor types consist predominantly of 
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squamous cell carcinoma involving the upper aerodigestive tract and account for 
greater than 90%, of head and neck cancers. 1  Because of the overwhelming 
majority of squamous cell cancer, it will be the focus of discussion.   
  
RISK FACTORS: 
 
The major risk factors for head and neck squamous cell carcinoma include 
exposure to tobacco, particularly through smoking, and alcohol.  Together 
smoking and alcohol consumption demonstrate a synergistic effect on the risk of 
developing HNSCC since both smoking and alcohol consumption directly 
traumatize mucosal surfaces. 1  Furthermore, exposure to tobacco smoke and 
alcohol increases the burden of carcinogenic compounds presented to the 
epithelial tissues.  Smoking confers a dose related risk with duration of use more 
important that intensity. 2  Alcohol is less important as an independent 
carcinogenic agent except with profound use.  However, alcohol exposure 
exacerbates the complex carcinogenic effects of tobacco.  Enzymatic systems 
important in detoxifying carcinogens exhibit polymorphisms that add to the 
genetic propensity for mutagenesis. 2   
 
In addition to toxic exposure from tobacco and alcohol, infection with certain 
viruses has been described to cause HNSCC.  Of particular interest, human 
papilloma virus (HPV) increases the risk of developing HNSCC. 1  Most 
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implicated are HPV variants 16 and 18. 2  These variants encode oncogenes E6 
and E7.  The tumor-suppressor gene p53 is downregulated by E6 while E7 
suppresses pRB. 2  HPV-related tumors are primarily located in the oropharynx 
and behave as a unique malignancy when compared to tumors caused by 
exposure to tobacco and alcohol. 1  As this discussion will focus on supraglottic 
carcinoma, it is beyond the scope of this paper to address HPV in its entirety.  
 
EMBRYOLOGY: 
 
The larynx is an elegant structure designed to allow phonation and help establish 
safe deglutition.  Embryologic development subdivides the larynx into the 
supraglottis, glottis, and subglottis.  The embryologic origin of the laryngeal 
subsites are important with regards to vascular and lymphatic anatomy as well as 
epithelial cellular structure.  These differences affect the clinical behavior of 
tumors presenting in each subsite.  
 
The supraglottis originates from the buccopharyngeal primordium of the third and 
fourth branchial arches. 1  The supraglottis contains the suprahyoid and 
infrahyoid epiglottis, aryepiglottic folds, arytenoids, and ventricular bands; also 
known as the false cords.  The embryologic development leads to arterial supply 
from the superior laryngeal arteries with accompanying bilateral lymphatic 
drainage. 1  Drainage, then, follows the superior laryngeal arteries to the carotid 
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sheath and further to the deep cervical chain in neck levels II and III. 3  The 
epithelium is composed of pseudostratified columnar cells in all areas except the 
lateral aryepiglottic folds and lateral epiglottis which are stratified squamous cells.  
Lymphatic vessels are quite superficial in the supraglottis, and with bilateral 
drainage, the risk of bilateral nodal metastasis at presentation is more likely.  For 
this reason, supraglottic malignancies tend to present at a more advance stage.1 
 
The glottis and subglottis are formed from the tracheobronchial premordium of 
the sixth branchial arch and involves and fusion of the lateral furrows. 1  The 
glottis contains the true vocal cords and associated anterior and posterior 
commissures. The arterial supply designated by this embryologic development is 
the inferior laryngeal arteries with associated lymphatic drainage.  The lateral 
union of the furrows creates a unilateral arterial supply and drainage of the glottis 
and subglottis.  Drainage of lymph follows the inferior laryngeal arteries to the 
prelaryngeal and pretracheal lymph nodes in neck level VI and further to the 
deep cervical chain in level IV. 3  The epithelium in this territory is made up of 
stratified squamous cells with three layers of lamina propria.  This leads to a 
deeper level of lymph drainage meaning that a tumor must invade more deeply 
before entering the lymphatic system. 1 This decreases the incidence of nodal 
metastasis at presentation and, due to the unilateral drainage pattern, tends to be 
unilateral unless the T stage is more advanced. 4 
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ANATOMY: 
 
The laryngeal superstructure includes one paired arytenoid cartilage and three 
unpaired cartilages: the epiglottis, thyroid cartilage, and cricoid cartilage.  The 
superior borders of the larynx include the superior surface of the epiglottis as well 
as the superior edge of the aryepiglottic folds.  The lingual surface of the 
suprahyoid epiglottis and the hyoepiglottic ligament make up the anterosuperior 
border.  Anterior borders of the larynx are the thyrohyoid membrane in the 
supraglottis, the thyroid cartilage in the glottis, and the cricothyroid membrane 
and the anterior arch of the cricoid cartilage in the subglottis.  The inferior edge is 
designated by a horizontal plane through the inferior edge of the cricoid cartilage.  
The aryepiglottic folds, arytenoid cartilages, interarytenoid space, and the 
posterior surface of the subglottic region comprise the posterior and lateral 
borders of the larynx.  Image 1 demonstrates the basic laryngeal structure. 1 
 
From an oncologic perspective, the most important anatomic details of the larynx 
are barriers to tumor spread and pathways that permit further tumor growth. 
Barriers to tumor progression within the larynx include the cartilaginous and 
ligamentous structures.  The conus elasticus, a thick fibroelastic structure in the 
glottic/subglottic region also prevents spread as does the cricothyroid 
membrane.1  The anterior commissure of the vocal cords also seems to be a 
barrier to glottic tumor spread.  Two main spaces are recognized as pathways 
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allowing spread of tumors within the larynx- the pre-epiglottic space and the 
paraglottic space (Image 2). 1  
 
Due to fenestrations in the epiglottic cartilage, the pre-epiglottic space (Image 2), 
which contains only fat and areolar tissue, can be invaded by tumor. 5  The pre-
epiglottic space is bounded superiorly by the hyoid bone, the hyoepiglottic 
ligament, and the valleculae of the hypopharynx.  The thyroid cartilage and the 
thyrohyoid membrane form the anterior border with the epiglottic cartilage and 
thyroepiglottic ligment make up the posterior border.  Laterally and inferiorly the 
pre-epiglottic space communicates with the paraglottic space. 6  Lymphatic 
vessels drain the paraglottic space bilaterally to neck zone II and III. 3   
 
The paraglottic space (Image 2) is prognostically important because progression 
of tumor into this potential space allows for spread to all three regions of the 
larynx, creating a transglottic neoplasm. 1  The space lies lateral to the true and 
false cords.  Superiorly it is in continuity with the pre-epiglottic space.  The medial 
borders are the quadragular membrane, an elastic supporting structure of the 
supraglottis, the conus elasticus, and the laryngeal ventricles.  Laterally, the 
thyroid cartilage and the pyriform sinus of the hypopharynx create borders.  The 
space progresses inferiorly to the cricothyroid membrane.  Glottic and 
supraglottic lesions are stages T3 if they involve the paraglottic space. 4  
 
Image 1: Anatomy of the laryngeal sites. !
Image from Cummings - Head and Neck surgery [1]
Image 2: Anatomy of the pre-epiglottic and paraglottic spaces !
Image from Cummings - Head and Neck surgery [1]
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STAGING: 
 
Staging follows the tenants of the TNM staging system to describe the extent and 
severity of a tumor.  Tumor characteristics including size and invasion generate 
the T stage.  Presence and laterality of nodal involvement provide N staging.  
The M stage refers to presence of metastatic disease.  By design, the overall 
stage of disease provides prognostic relevance.  Each characteristic is important 
in isolation, however, nodal spread and metastasis are particularly prognostic.  
TNM staging can carry two important prefixes - clinical or pathologic TNM 
staging.  Clinical examination and radiographic reveals a clinical (cTNM) stage.  
Biopsy of post-operative histopathology reveals a tumor’s pathologic (pTNM) 
stage.  A discussion of supraglottic staging with regards to prognosis will be 
discussed in a different section. 
 
In addition to TNM staging, the American Joint Commission on Cancer (AJCC) 
created a classification that weighs T, N, and M status to produce a stage I-IVc. 4  
AJCC staging offers a more simplified classification scheme that includes the 
prognostic relevance of nodal disease and metastasis.  The staging system 
demonstrates the prognostic significance of metastasis - any M1 tumor is 
automatically classified as stage IV. 4  The AJCC staging also demonstrates the 
importance of nodal involvement as a tumor with any nodal involvement is at 
Page 8 
 
least stage III while more advanced nodal disease such as bilaterality upstages 
the tumor to stage IVa. 4   
 
T STAGE: 
 
The T stage in laryngeal cancer depends on the subsite involved.  Since the 
focus of this paper is on supraglottic cancer, only supraglottic T staging will be 
described.  The T stage is categorized based on sites of invasion, vocal cord 
fixation, cartilaginous invasion, and extra-laryngeal involvement.  T1 lesions are 
localized to a single subsite of the supraglottis with retained vocal cord function. 
Invasion of more than one supraglottic subsite, glottic involvement, or spread to 
local mucosal surfaces of the valleculae, base of tongue, or pyriform sinus 
advance the stage to T2. 4  Normal vocal cord function without fixation must be 
present in T2 lesions.  Vocal cord fixation automatically upstages a tumor to T3. 4  
Invasion of the pre-epiglottic space, paraglottic space, post cricoid region, or 
minimal invasion into the inner cortex of the thyroid cartilage begets a T3 lesion 
as well. 4  T4 lesions are further subdivided into T4a and T4b. Invasion past the 
inner cortex of the thyroid cartilage or invasion of extra-laryngeal structures 
deliniate a T4a lesion. 1  Extra-laryngeal structures include the trachea, 
esophagus, thyroid tissue, or soft tissues of the neck such as the strap muscles 
or deep muscles of the tongue.  A T4b lesion invades deeply to the prevertebral 
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space, the mediastium, or encases the carotid artery. 4  The utility of T staging for 
therapeutic planning and prognosis will be discussed in a different section.  
 
N STAGE: 
 
All laryngeal tumors bear the same N classification system.  Presence, size, and 
laterality of nodal involvement generate the N stage.  The designation Nx is used 
when nodal involvement has yet to be or cannot be investigated.  An N0 tumor 
does not involve any lymph nodes.  It is relatively common for a cN0 lesion to be 
upstaged after neck dissection once histopathology has revealed occult nodal 
involvement.  Nodal involvement of 3 cm or less in a single node ipsilateral to the 
tumor is classified as N1. 4  The N2 categorization includes nodes less than 6cm 
in greatest dimension and is broken down into N2a, N2b, and N2c.  Nodes must 
remain ipsilateral to the tumor.  A single node greater than 3 cm but less than 
6cm is designated N2a. 4  Multiple ipsilateral nodes less than 6 cm classifies as 
N2b. 4  Bilateral or contralateral nodal involvement less than 6 cm is categorized 
as N2c. 4  Once a node is greater than 6 cm in greatest dimension, it is classified 
as an N3 node. 4  
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M STAGE: 
 
Of all the classifications in the TNM staging system, M stage is most binary.  
Patients without metastatic workup at said to have stage Mx disease.  The 
absence of distant metastasis classifies as M0.  The presence of any distant 
metastasis is termed M1. 4  The M1 status of a patient is the most foreboding 
classification system as it represents a tumor that has evolved to be able to 
invade the vascular system and invade at a distant site.  Numerous oncogenic 
and mutagenic derangements must have occurred to allow this. 1 
 
ADDITIONAL PROGNOSTIC MARKERS 
 
In addition to AJCC staging criteria and other clinical factors that are used to risk 
stratify patients and guide treatment, prognostic biologic factors, such as 
individual protein expression, mRNA expression patterns, and a few epigenetic 
biomarkers have been reported which can independently correlate with outcomes 
in laryngeal cancer.  The mutational landscape of head and neck squamous cell 
cancers was recently reported following whole exome sequencing.  Although 
novel mutations were identified, no correlation of mutational patterns with 
prognosis was performed.  In addition, it appears that different subsites of head 
and neck cancers may have different mutational trends. 7  Identifying mutational 
patterns that carry independent prognostic significance within a subsite would 
Page 11 
 
help guide future assessment of treatment outcomes and hopefully enable more 
individualized treatment approaches.  For this reason, a major goal in head and 
neck cancer continues to be to identify biologic markers that help to 
prognosticate outcomes and can guide treatment. 8  
 
After a review of the literature, the following genes were determined to be 
important and interesting targets for investigation: p53, Bcl-2, Ki67, p16ink4, 
BNIP3, TGM2, CD24, and Notch 1.  These candidate genes are involved in 
multiple pathways implicated in carcinogenesis or are shown to be associated 
with poorer prognosis in laryngeal squamous cell carcinoma.  As an apoptotic 
protein, p53 is a commonly mutated gene in solid tumors and is overexpressed in 
the majority of head and neck cancer.  However, results are inconsistent on p53’s 
prognostic relevance. 9  Bcl-2 is a key regulator of cell death and survival that is 
commonly expressed in laryngeal cancer with inconsistent prognostic correlation. 
9  Ki67 is a protein involved in cell proliferation and is used to estimate the 
proliferative rate of tumors.  Again, there is disagreement on the utility of Ki67 as 
a prognosticator – some previous studies have shown expression to predict 
poorer prognosis while others have not shown any correlation. 9  As a cell cycle 
regulator, p16ink4 has been implicated in poorer prognosis in patients with cancer 
of the larynx.  Its expression has also been shown to be anatomical location 
specific with predominance in the supraglottic and tonsillar regions. 9 
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The remaining candidate genes represent emerging players in head and neck 
cancer.  BNIP3 and TGM2 are target genes associated with action of the 
transcription factor hypoxia-inducible factor-1 (HIF-1a). 10  BNIP3 is normally 
upregulated by hypoxia and, as a member of the BCL-2 family, induces 
apoptosis.  BNIP3 has been shown to be silenced in tumor cells causing a failure 
of apoptosis and association with poorer survival and chemoresistance.  TGM2 
has been shown to enhance survival in hypoxic cells.  Increased expression of 
TGM2 has been associated with drug resistance in cancer and worse survival.  
CD24 has been studied in a variety of cancers but has recently been described in 
laryngeal cancer. 11  Down-regulation inhibits proliferation and induces apoptosis 
while increased expression increased tumor growth and propensity for 
metastasis.  In a recent study, CD24 expression was shown to be associated 
with tumor invasiveness and metastasis with high levels of expression associated 
with tumor progression. 12  Notch1 is a transmembrane signaling protein whose 
function in contextually related to the cells that it is found in.  In a recent study 
using exome sequencing, Notch1 was shown to acts as a tumor suppressor in 
head and neck SCC. 13 
 
SUPRAGLOTTIC CANCER: 
 
While it is convenient to discuss HNSCC as a single entity, it is becoming 
increasingly clear that each anatomical site is distinct with regards to diagnosis, 
Page 13 
 
natural history, and clinical response to treatment.  Furthermore, even subsites 
(Image 1) appear to represent clinically discrete diseases.  Supraglottic tumors 
have different behavior and prognosis than glottic and transglottic cancers. 14  
Additionally, treatment options for supraglottic squamous cell carcinoma have 
been evolving for the last two decades with an emphasis on functional organ 
preservation. 8  Supraglottic SCC should be considered a distinct clinical entity.  
For this reason, the remainder of the discussion will focus on the supraglottis. 
 
Supraglottic squamous cell carcinoma comprises 30-40% of larynx cancers and 
has unique risk for and patterns of regional metastatic spread and local extension 
compared to other larynx sub-sites. 1  Patterns of metastatic spread and 
extension are primarily due to embryologic characteristics previously discussed 
including superficially penetrating lymph vessels, bilateral drainage pattern, and 
proximity to the preepiglottic and paraglottic spaces.  These factors increased the 
likelihood that tumors had nodal involvement at the time of diagnosis. 15  
Furthermore, bilateral nodal involvement, more common to supraglottic tumors, 
involves a more advanced T stage and overall AJCC stage at time of diagnosis in 
many cases. 
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MODALITIES OF TREATMENT 
 
There has been considerable advancement in the available treatment options for 
supraglottic SCCA over the past decades.  Historically, a total laryngectomy 
dominated treatment of supraglottic tumors. 16  Over the last three decades, 
treatment options have been evolving and have increasingly consisted of organ 
preserving strategies. 8  Definitive radiotherapy and chemoradiotherapy treatment 
protocols as well as an emphasis on surgical techniques allowing partial 
laryngectomy have decreased the use of total laryngectomy (TL) in early stage 
tumors and raised questions about its employment even in more advanced 
stages.  The idea of non-operative treatment versus operative management of 
supraglottic lesions has given way to utilization of a multimodal approach.  
 
TOTAL LARYNGECTOMY 
 
In 1873, Billroth of Vienna performed the first total laryngectomy for laryngeal 
cancer. 1  This patient was deceased within 7 months.  A patient of Bottini of 
Turin who received a total laryngectomy in 1875 lived for 10 years. 1  With much 
advancement in anesthesiology, antibiotics, and surgical skill, the total 
laryngectomy became, and still is considered the gold standard treatment for 
supraglottic lesions.   
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The operative basics involve tracheostomy and a large apron incision allowing 
access to the midline neck structures.  The operation includes disruption of the 
hyoid bone and resection inferiorly to include from the epiglottis to below the 
cricoid.  Ultimately, a stoma is created and bilateral neck dissection in performed 
either concurrently or in a staged fashion. 1 
 
Indications of total laryngectomy include cartilaginous invasion of the tumor and 
extra-laryngeal spread. 4  Further evidence of advanced disease including 
subglottic extension, bilateral arytenoid joint involvement, and hypopharyngeal 
involvement typically indicates need for total laryngectomy. 4  In particular 
patients, were the risk of aspiration is high or will be detrimental due to underlying 
pulmonary disease may also lead to consideration of total laryngectomy.  In 
addition, salvage total laryngectomy may be necessary after failure of 
chemotherapeutic or radiation therapy.  Local recurrence and need for 
completion laryngectomy after partial laryngectomy can also occur. 1   
 
Complete evaluation of the fitness of the patient prior to the decision to proceed 
with any treatment, especially total laryngectomy, is essential.  Smee et al. 
investigated the importance of fitness for surgery in prognostic evaluation of a 
patient with supraglottic carcinoma. 17  He recapitulated what Piccirillo et al, 
Sjogren et al, and Paleri et al had demonstrated previously; that comorbidities 
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significantly affect survival. 17-20  Smee et al. went on to describe this in general 
as ‘fitness for surgery’. 17  
 
With the current range of organ preservation paradigms, it is particularly 
important however difficult to decide when total laryngectomy is appropriate.  
Principles of individualized and personalized therapy which involve the patient 
and their family intimately in the decision-making process will lead to better 
patient satisfaction.  To achieve this, discourse on the complete range of 
treatments available and appropriate for each patient’s lesion and comorbidities 
must be started early and ensure patient understanding.  The other options for 
treatment of supraglottic disease will be discussed below.  
 
OPEN SUPRAGLOTTIC LARYNGECTOMY 
 
Total laryngectomy, although gold standard treatment for supraglottic 
malignancies, involves considerable changes in quality of life.  In particular, the 
loss of voice and difficulty with swallowing can be exceedingly challenging for 
patients.  Techniques of organ preservation have been evolving in an attempt to 
mitigate the disruptive end-results of total laryngectomy.  Billroth first performed a 
hemilaryngectomy for malignancy in 1874 and techniques for partial laryngeal 
surgery have evolved significantly. 1  Open supraglottic laryngectomy, 
popularized first by Bocca in Europe and then Som, Ogura, and Kirchner in the 
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United States, is still used at some centers. 21  Benefits of the open supraglottic 
laryngectomy include preservation of vocal cord function and lower rates of 
tracheotomy dependence.  However, the laryngeal framework and supporting 
musculature is violated as part of the approach creating swallowing difficulties.  
Open partial laryngectomy operations have decreased with an increase in trans-
oral laser microsurgical techniques. 22  Merits of an endoscopic approach will be 
discussed in the next section. 
 
ENDOSCOPIC LASER SUPRAGLOTTIC LARYNGECTOMY 
 
Endoscopic use of the CO2 laser by Strong and Jako in 1972 lead to the 
establishment of transoral laser microsurgery (TLM) techniques for supraglottic 
laryngectomy. 23  A transoral approach eliminates the disruption of musculature 
involved in swallowing and maintains the laryngeal cartilagenous suprastructure.  
The transoral approach has gained popularity due to advancements in 
technology that have improved exposure and visualization.  The advent of laser 
dissection to remove tumors in a tailor made fashion while avoiding disruption of 
the laryngeal framework has helped to reinforce this surgical technique.  
Additionally, instant coagulation of tissue surfaces with the laser allows for 
piecemeal dissection of a tumor as opposed to the standard oncologic en-bloc 
resection. 24  Piecemeal dissection helps to tailor-make resection and increases 
the likelihood of a clean margin result.  
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The unique feature of true supraglottic lesions in that they do not involved the 
cricoarytenoid structures.  These structures are the basic functional units of the 
larynx and allow for vibration of the vocal cords.  Supraglottic laryngectomy, 
whether open or endoscopic, attempts to preserve the functional unit of the 
cricoarytenoids.  Criticism of transoral laser microsurgery tends to surround the 
issue of recurrence.  Numerous institutional outcomes studies have shown that 
recurrence lead to worse outcomes. 25  Radiation and chemotherapy regimens 
are used as primary treatment as well as in a multimodal fashion to treat the 
disease and decrease the chance of locoregional recurrence. 26  A discussion of 
primary radiation and chemotherapy and its utility in a multimodal approach to 
supraglottic carcinoma will follow.   
 
IMPLICATIONS OF OPERATIVE MANAGEMENT 
 
As with any significant operation, complications exist and can be considerable.  
Early complications include those common to all surgical intervention including 
risks of anesthesia, intraoperative bleeding, inability for complete resection, 
postoperative infection, and wound dehiscence. 27  Hematoma formation can be 
of particular issue due to potential for airway compression and compromise.  
Additionally, space-occupying hematoma can stress suture lines and 
compromise pharyngeal repairs.  Pharyngocutaneous fistula formation can occur 
and is especially a risk in patients with poor nutritional status.   
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Total laryngectomy leads to an impressive change in how an individual lives their 
life.   A laryngectomized patient will never again breath from their nose or mouth.  
As such, olfaction will no longer occur leading to profound changes in taste.  
Furthermore, they will have to undergo extensive therapy to learn to safely 
swallow in order to prevent aspiration.  Phonation will require either an 
electrolarynx, specialized speaking valve, or tracheoesophageal puncture.  With 
speech therapy, they will be able to develop esophageal speech that, in some 
cases, is intelligible.  In many cases, nutritional support with a percutaneous 
esophagogastrectomy tube will be required and, at times, lifelong.  
 
Organ preserving operative techniques are designed to mitigate the detrimental 
effects of a total laryngectomy.  Similar complications do arise even with the best 
organ preserving operation.  Temporary tracheostomy creation may be required 
during the operation and in cases of tracheal stenosis unrelieved by dilation in 
the postoperative setting.  Swallow function is affected, albeit to a lesser extent 
than in total laryngectomy, and can require nutritional support with a surgical 
feeding tube. 28  
 
Patients must be counseled on the risks, benefits, and changes that will affect 
their quality of life prior to undergoing any operation to treat their supraglottic 
lesion.  Laccourreye (2012) described that some patients desire cure, no matter 
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the means to achieve it. 29  Others may emphasize quality of life after diagnosis 
and treatment of their disease.  Treatment options must be tailor-made to the 
individual patient’s goals and objectives of life after diagnosis with a supraglottic 
malignancy. 29 
 
CHEMORADIOTHERAPY 
 
The emphasis of organ preservation in supraglottic carcinoma led to the 
investigation of non-operative radiation and chemotherapy-based regimens.  
When first employed as definitive treatment strategies for supraglottic carcinoma, 
radiation and chemotherapy based protocols touted similar oncologic and 
survival outcomes with vastly improved organ preservation. 30  Enhanced organ 
preservation, thus, implied better voice quality, swallowing function, and lower 
tracheostomy rates. 31  Additionally, another major advantage of 
chemoradiotherapy is preservation of surgery as an option for salvage in the 
setting of recurrent disease.  The use of chemoradiotherapy as part of the 
treatment for supraglottic neoplasms has evolved greatly over the last twenty to 
thirty years.  The current understanding of its utility will be evaluated while 
discussing multimodal therapy.  
 
Supraglottic lesions follow the same treatment principles of glottic neoplasms 
with the exception that the neck is always treated with radiation due to the higher 
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risk of occult nodal disease.  Radiation is delivered in multi-dose fractionations up 
to 70 Gy to the laryngeal site. 1  The neck is treated bilaterally in supraglottic 
disease.  A neck dissection may also be considered in definitive chemoradiation 
for supraglottic carcinoma.  The dosing schedule is rigorous and missed fractions 
have been shown to lead to worse outcomes. 32  Therefore, a patient’s ability to 
comply must be evaluated before radiation therapy is instituted.  
 
Chemotherapeutic approaches continue to progress as the biology and genetics 
of supraglottic squamous cell carcinogenesis is understood.  As a part of the 
armamentarium, chemotherapy acts to improve the tissue’s sensitivity to 
radiation.  Although never used in isolation for supraglottic malignancies, 
chemotherapy   particularly cisplatin-based therapy, is used either concomitantly 
with radiation therapy or as induction for definitive radiation-based treatment. 1  In 
addition to its use as part of primarily nonoperative treatment, induction 
chemotherapy can be used in a neoadjuvant approach to operative management 
of supraglottic lesions.  Finally, chemotherapy or chemoradiotherapy is often 
employed in the adjuvant setting to operative management. 33 
 
Chemoradiotherapy requires assessment of the entire clinical picture of a patient 
as systemic treatment can exacerbate other pathologies.  It must also be 
recognized that all treatments carry to possibility of significant mobility and 
mortality.  While surgical management is often criticized as disfiguring and can 
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profoundly alter a patient’s quality of life, radiation and chemotherapeutic 
treatment strategies have major impacts on an individual’s wellbeing.   
 
Side effects of radiotherapy depend on the size of the field requiring treatment.  
Early-stage, small lesions confer minimal complications from radiotherapy.  As 
the field of treatment grows, complications and side effects become more 
considerable.  Skin erythema, hoarseness, and dysphagia predominate the self-
limiting adverse radiation effects. 1  Hypothyroidism may occur due to the 
proximity of thyroid tissue to laryngeal structures.  Mucositis and xerositis are 
particularly irritating complications for patients and can last indefinitely.  
Radioprotecting medications such as amifostine help to prevent and limit these 
adverse effects. 1  Arytenoid edema and even necrosis are rarer but more 
serious complications.  Laryngeal edema and mucositis can increase risks of 
aspiration and ultimate respiratory compromise.  Odynophagia and dysphagia 
can lead to swallowing difficulty and, in some cases, necessitate the use of 
percutaneous esophagogastrectomy (PEG) tube placement for nutritional 
support.  Radiation also leads to significant neck fibrosis that can be 
uncomfortable to the patient and complicate operative management in the case 
of salvage surgery. 1 
 
Numerous investigations into biologic agents targeting supraglottic squamous cell 
carcinomas have introduced the possibility of increased refinement and 
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individualization of treatment based on a tumor’s genetic milieu.  It is beyond the 
scope of this thesis to discuss these agents.  However, an individualized 
approach to oncologic treatment of supraglottic lesions is a major goal and will 
considerably change the treatment of many head and neck neoplasms. 
 
MULTIMODAL THERAPY 
 
Currently, the major focus of treatment is to optimize the chance of cure while 
maximizing postoperative laryngeal function and minimizing complications.  
Multimodality therapy has become well established in effective treatment of the 
disease.  While total laryngectomy remains the gold standard oncologic option, 
respect for quality-of-life issues surrounding treatment of supraglottic carcinoma 
has pushed the field to think differently about approaching a patient with the 
disease.  Functional larynx preservation can be achieved surgically or non-
surgically. 31  Non-surgical modalities include primary radiation with or without 
concurrent chemotherapy.  Surgical options include using open or endoscopic 
techniques often followed by adjuvant radiation or chemoradiation.  Less 
aggressive surgery has been combined with adjuvant radiation or chemoradiation 
in a multi-modality approach to optimize survival in the face of improved post-
treatment laryngeal function. 34  The role of organ-preserving transoral surgery is 
not well defined in the overall multimodal treatment of supraglottic SCCA. 
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The advent of chemoradiation therapy as well as the amplification of operative 
techniques at organ preservation has increased the multidisciplinary approach to 
supraglottic cancer.  A patient’s healthcare team should include a medical 
oncologist, radiation oncologist, head and neck surgeon, oromaxillofacial 
surgeon, radiologist, as well as speech and swallow therapist and nutritional 
specialist.  The multidisciplinary approach has lead to improvements in patient 
satisfaction, outcomes, and research collaboration.  
 
THE CHALLENGE OF INSTITUTIONAL STUDIES 
 
As has been described, many therapeutic approaches exist for the treatment of 
supraglottic carcinoma.  Organ-preserving therapy, in the form of chemoradiation, 
has become popular in the United States.  Organ-preserving surgical techniques 
are available for treatment of early supraglottic carcinoma and appropriately 
selected advanced stages.  NCCN guidelines do not specify what is the preferred 
method of treatment except for specific advanced cases. 4  Anecdotally, 
preferences of practice vary with region within the United States.  Furthermore, 
international practice patterns are even more dramatically different judging by 
that the majority of literature on endoscopic and robotic resection emerges from 
Europe.  Groome et al (2003) compared management of supraglottic neoplasms 
in Ontario, Canada with a comparable cohort from the SEER Database. 35  They 
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identified profound differences in management practices, however, there were 
limited differences in outcomes.  Shah et al (1997) accrued data on over 16,000 
patients with squamous cell laryngeal cancer and observed diversity in the 
management of the disease across the US. 11  Differences in management 
existed even between site and stage.  
 
The differences in management strategy are demonstrated by the innumerable 
single institutional reviews emerging into the literature.  These reports attempt to 
describe what they believe to be the choice management strategy for supraglottic 
lesions.  Implicit in reports on a single management strategy is an inherent 
selection-bias of patients appropriate to receive the treatment of interest.    
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STATEMENT OF PURPOSE AND HYPOTHESIS 
 
RETROSPECTIVE REVIEW: 
 
Outcomes when transoral laser microsurgery (TLM) is part of a multimodality 
approach are not well defined.  Current guidelines for early and late stage 
disease include the use of TLM, open partial laryngectomy, radiation, 
chemotherapy, and total laryngectomy. 4  Current NCCN Head and Neck Cancer 
Guidelines for early stage supraglottic carcinoma (T1-2, N0; selected T3) is 
endoscopic resection +/- neck dissection, open partial supraglottic laryngectomy 
+/- neck dissection, or definitive radiation. 4  Advanced stage disease requires an 
increasingly multimodal approach with the possibility of total laryngectomy. 4  
What stands out in the guidelines is the absence of consensus on the optimal 
treatment option.  Therapeutic choice, therefore, becomes a factor of institutional 
trends and physician training.  An individualized approach to treatment of 
supraglottic carcinoma is essential but challenging due to the numerous different 
therapeutic modalities available.  Currently, attempts in the literature to evaluate 
larynx-preserving surgical approaches to supraglottic carcinoma tend to compare 
a highly selected patient group receiving the treatment of interest to previously 
published data.  Furthermore, conclusions of many studies commonly use the 
phrase “in a select group of cases” when weighing in on the utility of newer 
techniques.  This terminology leaves much open to interpretation.  What is 
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absent from published data, to our knowledge, is a comparison of a 
comprehensive cohort of patients receiving all modern treatments for supraglottic 
cancer.  Overall, the guidelines reflect a lack of consensus regarding optimal 
treatment and there is considerable treatment variation between centers.  
Although several series in the literature report functional and oncologic outcomes 
for selected patients with supraglottic squamous cell carcinoma treated with TLM 
there are no complete patient cohorts reporting outcomes with TLM as part of a 
multidisciplinary approach including the use of TLM, radiation, chemotherapy, 
and total laryngectomy. 
 
The purpose of this observational study is to report on the oncologic and 
functional outcomes in a complete cohort of patients without selection based on 
stage or treatment type.  The goal is to demonstrate how treatment of the 
disease, as a whole, has been approached at this institution. 
 
SEER VS. INSTITUTIONAL REVIEW: 
 
Innumerable institutional studies have investigated oncologic outcomes of the 
various treatment options for supraglottic neoplasms.  Many of these studies 
involve a specific treatment and, thus, patient population properly selected for 
that treatment.  This introduces a selection bias implicit in the institutional studies.  
Abstracting all institutional studies in the United States with a comparable SEER 
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cohort will allow direct visual comparison of the national trends in the disease 
with reports emanating from single institutions.  The purpose is to illuminate the 
difference between specific study outcomes and national trends in oncologic 
outcomes.   
 
HYPOTHESES: 
 
1. Oncologic outcomes will vary based on treatment with transoral laser 
microsurgery, total laryngectomy, or definitive radiation based therapy. 
 
2. Functional outcomes after transoral laser microsurgery is superior to both 
total laryngectomy and definitive chemoradiotherapy. 
 
3. Multimodality therapy in the form of adjuvant chemoradiation therapy is 
associated with improved survival.  
 
4. Survival reported in institutional studies will vary significantly from population 
based outcomes.  
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MATERIALS AND METHODS 
 
All portions of the retrospective review, systematic review of the literature, and 
SEER database analysis including, but not limited to: record review, database 
generation, and statistical analysis were conducted by the researcher responsible 
for this dissertation. 
 
RETROSPECTIVE REVIEW: 
 
Study Subjects 
The Yale University Institutional Review Board approved this study prior to data 
compilation and analysis.  Patients evaluated with supraglottic SCCA at Yale 
New Haven Hospital over a 5 year period between January 1, 2003 and 
December 31, 2007 were retrospectively identified.  Patients records were 
queried using ICD-9 codes for glottis (161.0), supraglottis (161.1), subglottis 
(161.2), laryngeal cartilage (161.3), and aryepiglottic fold (148.2).  Codes for all 
larynx subsites were reviewed to ensure inclusion of patients that may have been 
miscoded. CPT codes for open supraglottic laryngectomy (31367, 31368), 
horizontal/laterovertical/anterovertical/antero-latero-vertical hemilaryngectomy 
(31370, 31375, 31380, 31382), epiglottidectomy (31420), unlisted procedure of 
the larynx (31599), and total laryngectomy (31365, 31360) were also searched. 
Patients with pathologically confirmed supraglottic squamous cell carcinoma 
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were included.  The Yale Cancer Center Tumor Registry, a comprehensive 
registry of all cancer patients diagnosed, treated, or seen at Yale New Haven 
Hospital, was used as an additional check that all patients treated for supraglottic 
squamous cell caricinoma had been captured.  Patients with distant metastasis 
present at the time of diagnosis were excluded from analysis.  
 
A total of 60 patients were identified. One patient did not have complete staging 
information and was excluded.  Three patients treated with open supraglottic 
laryngectomy were excluded from survival and function analysis due to the small 
sample size in this treatment group.  The remaining 56 patients were included for 
analysis.  Patients were evaluated in a multidisciplinary fashion in the setting of a 
tumor board.    
 
Study Variables 
Clinical, pathological, functional, and survival data was collected from the medical 
records and entered into an Excel spreadsheet.  Demographic data included: 
gender, age at diagnosis, smoking/alcohol use, and race.  Pathologic and clinical 
data included tumor histology, location, TNM stage, AJCC stage, and margin 
status.  Treatment data collected included total laryngectomy (TL), transoral laser 
microsurgery (TLM), and radiation therapy including radiation with or without 
chemotherapy either in the definitive or adjuvant setting.  Post-treatment 
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functional outcome collected included incidence of PEG during treatment, PEG 
requirement after treatment, tracheostomy, and complications during treatment.   
 
Statistical Analysis 
Differences between treatment modalities and functional outcomes were 
measured with Chi-squared analysis.  Kaplan-Meier analysis was performed to 
establish overall survival outcomes.  Further assessment of survival differences 
between groups was done with Logrank and Cox regression analysis.  Disease-
specific survival could not be acceptably analyzed given the available data. 
Statistics were performed using SPSS, Kaplan-Meier curves were generated 
using R. 
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SEER VS. INSTITUTIONAL REVIEW: 
 
A systematic review on supraglottic squamous cell carcinoma survival outcomes 
was performed.  The databases queried included: Medline, Embase, Scopus, 
and Web of Science.  After a preliminary search of the literature, a MeSH 
analysis was generated to further refine search terms to enhance capture within 
the topic.   A total of 687 articles were discovered.  Only United States 
publications were of interest to increase the comparability between the reports 
and SEER outcomes.  385 international papers were excluded.  A total of 43 
publications included reports supraglottic squamous cell carcinoma.  The many 
excluded publications reported on glottic cancer, biomarker analysis, or were 
review articles without reported institutional outcomes.  Of the remaining 43 
publications, 18 articles reported data on survival statistics based on treatment 
modality for T1-T4 disease (Table 1).  From the data reported in these 
publications, survival statistics were back-calculated to produce descriptive 
survival statistics for each treatment modality investigated and for each stage 
represented.  No one single publication reported confidence intervals.  Therefore,  
confidence intervals were calculated using the formula 1.96 x SQRT ( proportion 
x ( 1 - proportion / n ) ) where proportion equals the reported or back-calculated 
survival.  The Survival Epidemiology and End Results (SEER) database for the 
National Cancer Institute was query for all patients with supraglottic squamous 
cell carcinoma between 1988-2004 was obtained.  The proprietary SEER 
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database manipulator was used to generate 2- and 5-year overall survival (OS) 
and disease specific survival (DSS).  Graphic representations of SEER derived 
survival statistics compared to institutionally reported survival were created using 
Graphpad Prism 6 and Apple Numbers.  
15,22,26,30,34,36-49 
 
 
 
 
 
 
Table 1: Selected Institutional Reports 
Articles selected from a systematic review of the literature that included survival statistics for 
each stage of disease. References in order of appearance: 
39,34,22,47,36,40,45,44,42,49,43,41,37,38,26,15,46,30,48 
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RESULTS 
 
RETROSPECTIVE REVIEW: 
 
Of the 56 patients eligible for analysis 22 (39%) were treated with TLM , 23 (41%) 
with XRT/CRT, and 11 (20%) with TL.  Neck dissection was performed in 17/22 
(77%) of patients treated with TLM and 10/11 (91%) of patients treated with TL. 
Adjuvant XRT or CRT was used in 82% of patients treated with TLM and in 82% 
of those treated with TL.  All patients treated with XRT/CRT received standard 
fractionation and dosage.  Average follow-up for all patients was 45 months. 
There was no significant difference in follow-up between treatment groups.   
 
Patient age, gender, race, T stage and AJCC stage were not associated with 5 
year overall survival (OS) (table 2).  Among tumor and patient characteristics only 
treatment modality was statistically associated with OS (p = 0.009), confirming 
our first hypothesis. Smoking status approached significance (p = 0.087).  There 
was not a significant difference in the distribution of stage between treatment 
groups (p = 0.454).   Five patients with pathologically T3 disease were treated 
with TL; 3 had large transglottic tumors or post-cricoid involvement, 1 was 
downstaged to T3 after being clinically staged T4, and 1 patient was unable to 
complete treatment with CRT due to renal failure and was subsequently 
treatment was converted to TL (table 3).  
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Local recurrence for TLM, TL, and XRT/CRT was 1/20 (5%), 0/11 (0%), and 1/11 
(9%) (Table 4).  Chronic gastrostomy tube use for TLM, TL, and XRT/CRT was 
3/20 (15%), 4/11 (36%) and 5/10 (50%).  Chronic tracheostomy for TLM, TL, and 
XRT/CRT was 0/21 (0%), 11/11 (100%), and 7/20 (35%) (Table 5).  Two year 
overall survival for TLM, TL, and XRT/CRT was 86% (18/21), 80% (8/10) and  
52% (12/23).  Kaplan-Meier survival curves by treatment modality are shown in 
Figure 1.  There was a significant difference in overall survival between treatment 
groups based on Log Rank analysis (p = 0.009), supporting hypotheris 1. No 
significant difference was found between AJCC stages (p = 0.471). 
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In unadjusted cox regression analysis (table 6), survival was significantly different 
between treatment groups (p = .015), indicating a survival risk to receiving XRT-
based therapy.  Receiving adjuvant radiation therapy following surgery conferred 
a significant survival benefit (HR = 3.475, p = 0.001).  This confirms our third 
hypothesis.  Age less than fifty was significantly associated with improved 
survival compared to age greater than seventy (HR = 11.363, p = 0.021).   
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In multivariate analysis (Table 7) , the significance of treatment remained when 
adjusting for AJCC stage.  This significance was lost, however, when adjusting 
for adjuvant therapy and incidence of recurrence.  When adjusting for stage of 
disease and patient age, XRT-based therapy carried a significant survival risk 
over receiving a TL (HR = 0.245, p = 0.028). Furthermore, patient age remained 
significant with a survival benefit in patients less than 50 years old (HR = 10.816, 
p = 0.032). 
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  Hazard Ratio 95% CI P-value 
Adjusted for: 
Tx, Stage, and Age 
Treatment Modality 
      TLM (v. XRT-based) 
      TL (v. XRT-based) 
 
AJCC Stage 
 
Age  
      50-70yo (v. <50yo) 
      >70yo (v. <50yo) 
 
0.721 
0.245 
 
 
 
 
6.704 
10.816 
 
0.343 - 1.515 
0.070 - .857 
 
 
 
 
0.861 - 52.211 
1.229 - 95.163 
0.084 
0.388 
0.028 
 
0.565 
 
0.089 
0.069 
0.032 
Adjusted for: 
Tx and Age 
Treatment Modality 
        TLM (v. XRT-
based) 
        TL (v. XRT-based) 
 
Age  
      50-70yo (v. <50yo) 
      >70yo (v. <50yo) 
 
0.681 
0.252 
 
 
6.041 
9.003 
 
0.329 - 1.409 
0.073 - 0.861 
 
 
0.780 - 46.806 
1.085 - 74.701 
0.078 
0.301 
0.028 
 
0.110 
0.085 
0.042 
Adjusted for: 
Tx and Adjuvant 
therapy 
Treatment Modality 
       TLM (v. XRT-based) 
        TL (v. XRT-based) 
 
Adjuvant Therapy  
      XRT  
      CT/XRT 
 
1.174 
0.670 
 
3.333 
2.722 
4.293 
 
0.435 - 3.173 
0.135 - 3.339 
 
1.099 - 10.106 
0.812 - 9.124 
1.122 - 16.434 
0.675 
0.751 
0.626 
 
0.033 
0.105 
0.033 
 Table 7. Multivariate Cox Regression Analysis. 
In an multivariate regression model, XRT-based therapy conferred a significant risk to 
survival only compared to TL when controlling for stage and age.  Receiving adjuvant 
therapy provided a significant survival benefit. Reference variables: XRT-based, Stage I, 
Age <50yo, adjuvant Tx, no locoregional recurrence 
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Figur
e 2. 
TL 
TLM 
XRT-based 
Figure 1: Kaplan-Meier Survival Curve based on Therapeutic Modality 
Survival curves for each therapeutic modality are shown. A log rank analysis demonstrated 
significance in survival (p = 0.009) 
Figure 2: Kaplan-Meier Survival Curve based on AJCC Stage 
Survival curves for each therapeutic modality are shown. A log rank analysis demonstrated 
lack of statistically significant difference in survival (p = 0.471). 
IV 
III 
 
I 
 
II 
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SEER VS. INSTITUTIONAL REVIEW 
A visual representation of institutionally reported survival statistics compared to 
SEER database generated survival statistics are shown in Figures 3-5. The 2- 
and 5-year overall survival and disease specific survival generated from the 
query of the SEER Database were used as zero lines on the graphic 
representations.  The number of institutional reports included on the graphics 
were dependent on what statistical outcomes each publication presented.   
Figure 4: 5-year Disease Specific Survival 
SEER-derived 5yr DSS for supraglottic cancer is 67%. Individual institutional reported 5yr DS are demonstrated with 
hazard ratios. Bracketed numbers reference articles shown in Table 1.  
SSL = subtotal supraglottic laryngectomy, ND = neck dissection, RT = Radiation, TL = total laryngectomy 
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Figure 3: 5-year Overall Survival 
SEER-derived 5yr OS for supraglottic cancer is 42%. Individual institutional reported 5yr OS are demonstrated with 
hazard ratios. Bracketed numbers reference articles shown in Table 1.  
SSL = subtotal supraglottic laryngectomy, ND = neck dissection, RT = Radiation, TL = total laryngectomy 
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These findings support our fourth hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Survival statistics for each stage of disease 
SEER-derived survival statistics for supraglottic cancer is presented along side individual 
institutional reported survival statistics demonstrated with hazard ratios. Bracketed numbers 
reference articles shown in Table 1. 
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DISCUSSION 
 
Since Billroth first performed a hemilaryngectomy for malignancy in 1874, 
techniques for partial laryngeal surgery for SSCC have evolved significantly. 50  
Open supraglottic laryngectomy, popularized first by Bocca in Europe and then 
Som, Ogura, and Kirchner in the United States, is still used at some centers. 21 
Endoscopic use of the CO2 laser by Strong and Jako in 1972 lead to the 
establishment of TLM techniques for supraglottic laryngectomy. 23 
 
There remains controversy in the management strategy for supraglottic SCCA.  
The historical use of total laryngectomy as the gold standard treatment modality 
gave way in to primary treatment with chemoradiation to maximize laryngeal 
preservation, saving surgery for salvage.  The initial role of chemoradiation-
based therapy has been supported by landmark studies, most notably the 
Veteran Affairs Larynx Cancer Study4 and the RTOG 91-11study. 51  These trials 
have been essential to improving larynx preservation.  Overall, the application of 
radiation and chemotherapy at the population level for organ preservation 
remains associated with some controversy. 52  These and other commentaries 
challenge the application of the landmark VA and RTOG studies to a broad-
based population. 8  The generalizability of these findings are controversial 
especially after a report by Hoffman, et al. observed that laryngeal cancer is the 
only anatomical site that has seen decreased survival in the US over the last two 
Page 44 
 
decades. 8  The supraglottic subsite appears to play an important role in the 
observed diminished survival.  Hoffman, et al. went on to show that this decrease 
in survival coincides with the change in treatment priorities to less aggressive 
primary treatment with chemoradiation rather than surgery. 8  This observation 
was confirmed by Zhang et al. however, this group did not find a decreased 
survival in patients receiving RT since 1994. 53  In a population based study, 
Chen & Halpern concluded that TL provides best chance of survival in patients 
with advanced disease. 32  Developments in surgical technique have been 
occurring, resulting in better functional outcomes.  Chemoradiation regimens 
have been refined as well.  However, there is a lack of consensus on what is the 
best practice for treating supraglottic lesions.  
 
The treatment options for supraglottic SCCA have evolved over the last two 
decades.  The goal of oncologic cure and functional laryngeal preservation 
influenced the predominant use of non-operative management with radiation and 
chemoradiation in the United States.  Total laryngectomy and subtotal 
supraglottic laryngectomy via an open or endoscopic approach are also options 
within the modern armamentarium for supraglottic SCCA.  Numerous institutional 
studies have been published reporting outcomes for open and transoral 
supraglottic laryngectomy and have been paramount is describing the feasibility 
and efficacy of each modality. 54  In general, these reports include series of 
patients selected based on tumor characteristics including stage as well as 
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patient characteristics including fitness for surgery, and do not report patients 
treated with alternate modalities.  These studies commonly focus on a particular 
technique to report on or compare to previously published results.  The benefit 
has been the introduction and validation of important techniques used to treat 
supraglottic cancer.  However, many studies involved precise selection criteria 
based on tumor characteristics or stage of disease.  Inherent to such selection 
processes is a level of bias introduced to statistical analysis.  Furthermore, in the 
clinical setting the decision on what treatment to offer involves countless 
individual patient parameters.  Study selection criteria augments the reality of 
clinical medicine - practicing medicine involves offering treatment options to 
patients where as, in the research environment, patients are selected for a 
certain treatment.  To some degree, because of this, the role of transoral laser 
microsurgery in the multidisciplinary care of supraglottic squamous cell cancer 
remains ill defined.   
 
The present study took an approach similar to clinical medicine - the only 
selection criteria was that a patient had a supraglottic squamous neoplasm.  This 
study is the first that we are aware of which includes a complete cohort of 
patients with supraglottic squamous cancer treated with multiple modalities 
including TLM.  Multiple treatment modalities were considered before a specific 
treatment was recommended for each patient; an intent-to-treat design. Patients 
of all stages were included.  This study design allowed a side-by-side analysis of 
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all treatment types and stages without issues of dropout or crossover.  Given the 
inclusion of many modern treatment modalities and all stages of disease, the 
study represents a less biased comparison in the analysis of functional and 
survival outcomes.  The result is a reporting of our institutional approached to 
supraglottic cancer. 
 
The results of the current study demonstrate a diminished survival in patients 
treated with XRT-based therapy when compared to TL and TLM.  When 
controlling for both stage and age, XRT-based treatment nonetheless carries a 
survival risk when compared to TL.  This reduced survival in the radiotherapy 
group may be secondary to poorer performance status or other confounding 
factors not captured in the available data.  Poor performance status may have 
precluded operative management and, as Smee et al. illustrate, fitness for 
surgery significantly affects overall survival. 17   
 
Transoral laser microsurgery was superior to XRT-based treatment in direct 
comparison and when controlling for stage of disease.  Interestingly, the 
significance of the difference was lost when controlling separately for age, 
adjuvant treatment, and recurrence.  This may represent the difficult nature of 
this disease, but may also emphasize important factors to survival such as the 
use of adjuvant treatment and the impact of disease recurrence.  In addition, a 
dramatic decrease in survival at the 5-year point was seen in both TLM and XRT-
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based treatment.  Interpretation of this observation becomes difficult as the 
sample-size is small. 
 
In this series, the prescription of adjuvant therapy significantly improved survival 
when adjusting for treatment.  More specifically, chemoradiation-based adjuvant 
therapy conferred a survival advantage in this cohort.  Interestingly, when 
controlling for adjuvant therapy, there were no survival differences seen between 
treatment groups.  Given the large percentage of patients getting adjuvant 
treatment after TL and TLM, these results reinforce the importance of a 
multimodal approach to supraglottic SCCA.  This finding deserves further 
exploration to explain the importance of chemotherapy-based adjuvant treatment 
in the setting of surgical management of supraglottic neoplasms. 
 
Several prognostic factors reported in the literature are reevaluated in this cohort. 
Age greater than 70 years old emerged as a significant survival risk in our data 
analysis. The importance of patient age has been reported in the literature. 47  
Disease recurrence is an important prognostic factor implicated in survival 
outcomes. 55  Contrary to expectation, recurrence did not have a significant 
impact on survival in univariate or multivariate analysis, although there was a 
significant difference in the incidence of recurrence between treatment groups in 
this study. This is inconsistent with Sessions et al. who associated decreased 
survival with recurrence. 47  The differences in this study may be explained by the 
Page 48 
 
size of this study as well as the inclusion of all treatment groups.  For instance, 
Sessions et al. did not include patients receiving chemotherapy-based treatment 
in the data that lead to their conclusion associating recurrence with decreased 
survival. 47   Further investigation should focus on the importance of margin status 
and its relation to disease recurrence in the analysis of survival outcomes.  Other 
clinical prognosticators typically described in the literature include nodal status 
and specific site involvement, such as the preepiglottic space and the vallecula. 
56  The relatively small size of this study may be responsible for those not 
reaching statistical significance in our study.  
 
Patient quality of life measures are important in the treatment of SSCC because 
of the significant morbidity in speech and swallow function that can occur as a 
result of these tumors and its treatment.  Considerations of quality-of-life add to 
the complex nature of therapeutic decision-making.  As Laccourreye et al. aptly 
describe in their recent study, a careful evaluation of the attitudes and opinions a 
patient has regarding their own survival or functional impairments is essential. 29  
Multiple authors have published on advantages of post-operative function after 
TLM including reduced impact on swallowing, decreased length-of-stay, and 
shorter PEG tube and tracheostomy duration. 32  In our study, functional 
outcomes were comparable across treatment groups except for where 
differences were anticipated, such as the TL group.  Although not statistically 
significant, the data illustrated the performance benefit of TLM compared to all 
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other treatments.  No patients in the TLM group were chronically tracheotomy 
dependent.  Percutaneous endoscopic gastrostomy (PEG) tube requirement in 
the TLM group was 15%, but lower than in both the TL and XRT groups.  This 
study demonstrates that XRT-based treatment is not without morbidity and, on 
the whole, has a higher incidence of functional impairment when compared to 
TLM.  The rates of functional outcome measures are high for each treatment 
modality compared to other published series, which may be due in part to 
comorbidity and pre-treatment health status.  
 
The study is limited by its retrospective nature.  Records were incomplete in 
some cases, limiting our ability to analyze post-operative function, recurrence, 
and cause of death.  Moreover, while the size of the entire cohort is within the 
upper range of previously published series, subgroup sample sizes are small, 
making it difficult to draw conclusions between groups.  A larger sample size 
would improve multivariate comparisons by increasing the ability to control 
survival analysis for multiple factors, simultaneously. 
 
As has been previously discussed, numerous institutions have published 
oncologic outcomes for a variety of treatment modalities.  These reports, as a 
whole, tend to investigate a single modality of therapy.  As alluded to, such 
reports may introduce a degree of selection bias as patients have already been 
selected as appropriate candidates for the treatment of interest.  We 
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hypothesized that this introduces outcomes that are not entirely representative of 
the overall nature of the disease.  Figures 3-5 show the reported oncologic 
survival compared to national survival statistics generated by the SEER 
Database.  As hypothesized, institutionally reported survival tends to be superior 
to national survival.  This trend is especially consistent with reported overall 
survival, which is arguably more important to a patient than disease specific 
survival.  When extrapolated by stage, institutional survival remains elevated 
above national statistics primarily for early stage disease.  There is increased 
variation in survival at more advanced stage disease likely representing the 
difficulty treating complex lesions with more aggressively invasive components.  
 
The graphics presented here represent a birds-eye view of survival after treating 
supraglottic carcinoma.  There is a range of survival reported by single 
institutions and they tend to be superior to national survival trends.  What this 
demonstrates is a need for emphasis on multi-institutional trials or increased 
utilization of population-based investigation.  Taken in the context of our 
retrospective study in which we attempted to report with an intent-to-treat model 
looking at oncologic and functional outcomes of patients with supraglottic 
neoplasms, efforts should be made to further investigate the successes in 
treating the disease in a comprehensive fashion.  
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CONCLUSION 
 
Today, the complexity of supraglottic cancer is further complicated by the variety 
of treatment options available and their application in a multimodal fashion.  
Since this study involved the observations of a comprehensive cohort, these 
results are important to the overall treatment of a patient presenting with primary 
supraglottic SCCA.  Our study reports a comprehensive cohort of patients with 
SSCC treated in a multimodality fashion, including the use of TLM. Total 
laryngectomy performed the best in terms of survival. Amongst the organ 
preserving treatments, XRT-based primary therapy was associated with 
decreased survival risk, although selection bias would be expected with poorer 
performing patients being treated with XRT.  The increasing expertise in 
microsurgical and CO2 laser-based resection has improved upon the surgical 
options for functional laryngeal preservation.  As reinforced by this study, 
transoral laser microsurgery, especially when employed in a multimodal 
approach including adjuvant chemoradiotherapy, offers acceptable oncologic 
results and good functional outcomes.   
 As a comprehensive approach to studying the treatment of supraglottic 
cancer, this study has important relevance.  Future investigation into supraglottic 
SCCA deserves a well-designed and comprehensive prospective observation 
similar to this series.  This study and further prospective studies will help to 
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improve the understanding of therapeutic decision-making and lead to better 
success with treating supraglottic cancer.
Page 53 
 
Bibliography 
 
1. Cummings CW. Cummings otolaryngology head & neck surgery. 4th ed. 
Philadelphia, Pa.: Elsevier Mosby; 2005. 
2. Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for 
head and neck cancer. Seminars in oncology 2004;31:726-33. 
3. Lucioni M. Practical guide to neck dissection. 1st ed. New York: Springer; 
2007. 
4. Pfister DG, Ang K, Brockstein B, et al. NCCN Practice Guidelines for Head 
and Neck Cancers. 2000:163-94. 
5. Zeitels SM, Vaughan CW. Preepiglottic space invasion in&quot; 
early&quot; epiglottic cancer. The Annals of otology 1991. 
6. Dayal VS, Bahri H, Stone PC. Preepiglottic Space: An Anatomic Study. 
Archives of Otolaryngology—Head &amp; Neck Surgery 1972;95:130-3. 
7. Bauman JE, Michel LS, Chung CH. New promising molecular targets in 
head and neck squamous cell carcinoma. Current opinion in oncology 
2012;24:235-42. 
8. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal Cancer in the United 
States: Changes in Demographics, Patterns of Care, and Survival. The 
Laryngoscope 2009;116:1-13. 
9. Holgersson G, Ekman S, Reizenstein J, et al. Molecular profiling using 
tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer 
treated with radiotherapy. Cancer genomics & proteomics 2010;7:1-7. 
10. Jin T, Lin H-X, Lin H, et al. Expression TGM2 and BNIP3 have prognostic 
significance in laryngeal cancer patients receiving surgery and postoperative 
radiotherapy: A retrospective study. Journal of Translational Medicine 
2012;10:64. 
11. Shah JP, Karnell LH, Hoffman HT, Ariyan S. JAMA Network | JAMA 
Otolaryngology—Head &amp; Neck Surgery | Patterns of Care for Cancer of the 
Larynx in the United States. Head &amp; Neck 1997. 
Page 54 
 
12. Shi Y, Gong H-L, Zhou L, Tian J, Wang Y. CD24: A Novel Cancer 
Biomarker in Laryngeal Squamous Cell Carcinoma. ORL 2012;74:78-85. 
13. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head 
and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. 
Science 2011;333:1154-7. 
14. Silvestri F, Bussani B, Stanta G, Cosatti C, Ferlito F. Supraglottic versus 
Glottic Laryngeal Cancer: Epidemiological and Pathological Aspects. ORL 
1992;54:43-8. 
15. HICKS JR WL, KOLLMORGEN DR, KURIAKOSE MA, et al. Patterns of 
nodal metastasis and surgical management of the neck in supraglottic laryngeal 
carcinoma. Otolaryngology--Head and Neck Surgery 1999;121:57-61. 
16. Maddox PT, Davies L. Trends in Total Laryngectomy in the Era of Organ 
Preservation: A Population-Based Study. Otolaryngology--Head and Neck 
Surgery 2012;147:85-90. 
17. Smee RI, De-Loyde KJ, Broadley K, Williams JR. Prognostic factors for 
supraglottic laryngeal carcinoma: Importance of the unfit patient. Head &amp; 
Neck 2012:n/a-n/a. 
18. Paleri V, Wight RG, Silver CE, et al. Comorbidity in head and neck cancer: 
a critical appraisal and recommendations for practice. Oral Oncol 2010;46:712-9. 
19. Piccirillo JF, Spitznagel EL, Jr., Vermani N, Costas I, Schnitzler M. 
Comparison of comorbidity indices for patients with head and neck cancer. 
Medical care 2004;42:482-6. 
20. Sjogren EV, Wiggenraad RG, Le Cessie S, Snijder S, Pomp J, Baatenburg 
de Jong RJ. Outcome of radiotherapy in T1 glottic carcinoma: a population-based 
study. European archives of oto-rhino-laryngology : official journal of the 
European Federation of Oto-Rhino-Laryngological Societies 2009;266:735-44. 
21. Bocca E. SUPRAGLOTTIC CANCER. The Laryngoscope 1975;85:1318-
26. 
22. Grant DG, Salassa JR, Hinni ML, Pearson BW, Hayden RE, Perry WC. 
Transoral laser microsurgery for carcinoma of the supraglottic larynx. 2007. 
Page 55 
 
23. Strong MS, Jako GJ. Laser surgery in the larynx. Early clinical experience 
with continuous CO 2 laser. Ann Otol Rhinol Laryngol 1972;81:791-8. 
24. Mihashi S, Jako GJ, Incze J, Strong MS, Vaughan CW. LASER 
SURGERY IN OTOLARYNGOLOGY: INTERACTION OF CO 2LASER AND 
SOFT TISSUE. Annals of the New York Academy of Sciences 1976;267:263-94. 
25. Lu Z-m, Song X-h, Zhang S-y, et al. [Long-term outcome of CO₂ laser 
microlaryngoscopic treatment for laryngeal cancer]. Zhonghua zhong liu za zhi 
[Chinese journal of oncology] 2012;34:473-6. 
26. DEVINENI VR, SIMPSON JR, SESSIONS D, et al. Supraglottic Carcinoma 
- Impact of Radiation-Therapy on Outcome of Patients with Positive Margins and 
Extracapsular Nodal Disease. Laryngoscope 1991;101:767-70. 
27. Vilaseca-González I, Bernal-Sprekelsen M, Blanch-Alejandro J-L, 
Moragas-Lluis M. Complications in transoral CO2 laser surgery for carcinoma of 
the larynx and hypopharynx. Head &amp; Neck 2003;25:382-8. 
28. Rodrigo JP, Coca-Pelaz A, Suárez C. The Current Role of Partial Surgery 
As a Strategy for Functional Preservation in Laryngeal Carcinoma. Acta 
Otorrinolaringologica (English Edition) 2011;62:231-8. 
29. Laccourreye O, Malinvaud D, Holsinger FC, Consoli S, Ménard M, Bonfils 
P. Trade-off between survival and laryngeal preservation in advanced laryngeal 
cancer: the otorhinolaryngology patient&apos;s perspective. The Annals of 
otology, rhinology, and laryngology 2012;121:570-5. 
30. Shimm DS, Coulthard SW. Radiation Therapy for Squamous Cell 
Carcinoma of the Supraglottic Larynx. American Journal of Clinical Oncology 
1989;12:17. 
31. Ambrosch P, Fazel A. Functional organ preservation in laryngeal and 
hypopharyngeal cancer. GMS current topics in otorhinolaryngology, head and 
neck surgery 2011;10:Doc02. 
32. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal 
cancer. Archives of Otolaryngology—Head &amp; Neck Surgery 2007;133:1270-
6. 
33. Yoon TM, Lee JK, Cho JS, Lim SC, Chung W-K. Role of concurrent 
chemoradiation in laryngeal preservation for supraglottic cancer. Journal of 
Page 56 
 
otolaryngology - head &amp; neck surgery = Le Journal d&apos;oto-rhino-
laryngologie et de chirurgie cervico-faciale 2010;39:142-9. 
34. Agrawal A, Moon J, Davis RK, et al. Transoral Carbon Dioxide Laser 
Supraglottic Laryngectomy and Irradiation in Stage I, II, and III Squamous Cell 
Carcinoma of the Supraglottic LarynxReport of Southwest Oncology Group 
Phase 2 Trial S9709. Archives of Otolaryngology—Head &amp; Neck Surgery 
2007;133:1044-50. 
35. Groome PA, O&apos;Sullivan B, Irish JC, et al. Management and outcome 
differences in supraglottic cancer between Ontario, Canada, and the 
Surveillance, Epidemiology, and End Results areas of the United States. Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology 
2003;21:496-505. 
36. Alpert TE, Morbidini-Gaffney S, Chung CT. Radiotherapy for the Clinically 
Negative Neck in Supraglotti... : The Cancer Journal. The Cancer … 2004. 
37. Chan AW, Ancukiewicz M, Carballo N, Montgomery W, Wang CC. The 
role of postradiotherapy neck dissection in supraglottic carcinoma. International 
journal of radiation oncology, biology, physics 2001;50:367-75. 
38. Chiu RJ, Myers EN, Johnson JT. Efficacy of routine bilateral neck 
dissection in the management of supraglottic cancer. Otolaryngology--head and 
neck surgery : official journal of American Academy of Otolaryngology-Head and 
Neck Surgery 2004;131:485-8. 
39. Ganly I, Patel SG, Matsuo J, et al. Predictors of outcome for advanced-
stage supraglottic laryngeal cancer. Head &amp; Neck 2009;31:1489-95. 
40. Hinerman RW, Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, 
Robbins KT. Carcinoma of the supraglottic larynx: Treatment results with 
radiotherapy alone or with planned neck dissection. Head and Neck-Journal for 
the Sciences and Specialties of the Head and Neck;24:456-67. 
41. Lee NK, Goepfert H, Wendt CD. Supraglottic Laryngectomy for 
Intermediate-Stage Cancer. Laryngoscope 1990;100:831???6. 
42. Mendenhall WM, Parsons JT, Mancuso AA, Stringer SP, Cassisi NJ. 
Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an 
alternative to surgery. Head & neck 1996;18:24-35. 
Page 57 
 
43. Mendenhall WM, Parsons JT, Stringer SP, Cassisi NJ, MILLION RR. 
Carcinoma of the Supraglottic Larynx - a Basis for Comparing the Results of 
Radiotherapy and Surgery. Head and Neck-Journal for the Sciences and 
Specialties of the Head and Neck 1990;12:204-9. 
44. Myers EN, Alvi A. Management of Carcinoma of the Supraglottic Larynx: 
Evolution, Current Concepts, and Future Trends. The Laryngoscope 
1996;106:559-67. 
45. Nakfoor BM, Spiro IJ, Wang CC, Martins P, Montgomery W, Fabian R. 
Results of accelerated radiotherapy for supraglottic carcinoma: a Massachusetts 
General Hospital and Massachusetts Eye and Ear Infirmary experience. Head 
and Neck-Journal for the Sciences and Specialties of the Head and Neck 
1998;20:379-84. 
46. Nguyen-Tan PF, Le QT, Quivey JM, et al. Treatment results and 
prognostic factors of advanced T3-4 laryngeal carcinoma: The University of 
California, San Francisco (UCSF) and Stanford University Hospital (SUH) 
experience. International journal of radiation oncology, biology, physics 
2001;50:1172-80. 
47. Sessions DG, Lenox J, Spector GJ. Supraglottic Laryngeal Cancer: 
Analysis of Treatment Results. The Laryngoscope 2005;115:1402-10. 
48. SPECTOR JG, SESSIONS DG, EMAMI B, SIMPSON J, HAUGHEY B, 
FREDRICKSON JM. Squamous-Cell Carcinomas of the Aryepiglottic Fold - 
Therapeutic Results and Long-Term Follow-Up. Laryngoscope 1995;105:734-46. 
49. Weber PC, Johnson JT, Myers EN. The Impact of Bilateral Neck 
Dissection on Pattern of Recurrence and Survival in Supraglottic Carcinoma. 
Archives of Otolaryngology—Head &amp; Neck Surgery 1994;120:703-6. 
50. TUCKER HM. CONSERVATION LARYNGEAL SURGERY IN THE 
ELDERLY PATIENT. Laryngoscope 1977;87:1995???9. 
51. aurthor N. Induction Chemotherapy plus Radiation Compared with Surgery 
plus Radiation in Patients with Advanced Laryngeal Cancer. The New England 
journal of medicine 1991;324:1685-90. 
52. Olsen KD. Reexamining the treatment of advanced laryngeal cancer. 
Head & neck 2010;32:1-7. 
Page 58 
 
53. Zhang H, Travis LB, Chen R, et al. Impact of radiotherapy on laryngeal 
cancer survival. Cancer 2011;118:1276-87. 
54. Canis M, Martin A, Ihler F, et al. Results of transoral laser microsurgery for 
supraglottic carcinoma in 277 patients. European Archives of Oto-Rhino-
Laryngology 2013. 
55. Forastiere AA. Larynx preservation and survival trends: Should there be 
concern? Head &amp; Neck 2009:NA-NA. 
56. Peretti G, Piazza C, Ansarin M, et al. Transoral CO2 laser microsurgery 
for Tis-T3 supraglottic squamous cell carcinomas. European Archives of Oto-
Rhino-Laryngology 2010;267:1735-42. 
 
 
